Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706760 | 0.92 | APLNR (0.43) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 | |
| SCHEMBL3713241 | 0.91 | APLNR (0.38) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 | |
| SCHEMBL3710810 | 0.91 | APLNR (0.35) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 | |
| SCHEMBL3708521 | 0.90 | POLB (0.37) | APLNRSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL3708894 | 0.89 | APLNR (0.35) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 | |
| SCHEMBL3709967 | 0.88 | APLNR (0.38) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 | |
| SCHEMBL3711008 | 0.88 | APLNR (0.35) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 | |
| SCHEMBL3708955 | 0.86 | CCR2 (0.35) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 | |
| SCHEMBL3703439 | 0.85 | APLNR (0.34) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 | |
| SCHEMBL3699737 | 0.85 | APLNR (0.34) | APLNRSMN1; SMN2NPC1NFKB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471782-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AGTR2, AGTR1, PPARA | APLNR 268/4885SMN1; SMN2 1969/4885NPC1 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.